Adding chemotherapy to standard prostate cancer treatment may extend life expectancy

May 14, 2015, University of Warwick

New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared to those who received standard therapy alone.

In contrast, adding to standard therapy did not affect survival, and adding the combination of zoledronic acid and docetaxel was not more effective than adding just docetaxel.

The STAMPEDE trial was led by Professor Nicholas James, Director of the Cancer Research Unit at the University of Warwick in Coventry, United Kingdom and Consultant in Clinical Oncology at Queen Elizabeth Hospital Birmingham. It was run from the MRC Clinical Trials Unit at UCL and supported by Cancer Research UK.

STAMPEDE is the largest randomized clinical trial of treatment for with prostate cancer ever conducted, with more than 6,500 patients enrolled since 2005. The research team will be talking about the trial at the American Society of Clinical Oncology's Annual Meeting on 31 May in the US.

Professor James said: "We hope our findings will encourage doctors to offer docetaxel to men newly diagnosed with , if they are healthy enough for chemotherapy. Men with non-metastatic advanced prostate cancer may also consider docetaxel as part of upfront therapy, as it clearly delays relapse.

"It's also clear that zoledronic acid does not benefit these patients and should not be offered as an upfront treatment for advanced prostate cancer."

The standard of care (SOC) treatment was at least three years of , with local radiation for suitable patients.

The researchers will be reporting results on 2,962 hormone-naïve men who started long-term hormone therapy for the first time. The men were assigned to four different treatment arms: standard of care (SOC), SOC with docetaxel for 6 cycles, SOC with zoledronic acid for 2 years, and SOC with both docetaxel and zoledronic acid. About 60% of the patients had metastatic disease when joining the trial and the rest had high-risk, non-metastatic prostate cancer.

After a median follow-up of 42 months, 948 men had died. Overall survival was on average ten months longer in the docetaxel arm compared to the SOC arm (67 vs. 77 months) with a relative improvement of 24% (hazard ratio 0.76). For the subset of patients with metastatic disease, the average improvement in overall survival was even higher, 22 months (from 43 vs. 65months). Importantly, docetaxel also extended the time to relapse by 38% in all patients (hazard ratio 0.62).

Two previous, smaller trials have reported results on using docetaxel in the hormone naïve metastatic setting. These trials showed conflicting results. CHAARTED in the USA reported in the plenary session of ASCO 2014 showed a survival advantage; GETUG-15 in France did not. STAMPEDE goes a long way in clarifying the role of docetaxel in men with newly diagnosed high risk prostate cancer. The trial also included a larger and broader patient population than those trials, comprising men with both metastatic and advanced non-metastatic prostate cancer. This includes nearly 600 men with non-metastatic node-negative disease similar to RTOG 0521 which is being reported in the same session of ASCO 2015.

According to the authors, the overall findings of this study suggest that men with newly diagnosed metastatic prostate cancer should be offered docetaxel as part of their initial therapy. Doctors may also discuss the option of adding docetaxel with patients who have advanced, non-metastatic , given the reduction in risk of relapse seen in this study. However, longer follow up is needed to determine if there is any survival advantage in men with non-metastatic disease.

While docetaxel was associated with some additional toxicity compared to SOC alone, the side effects were manageable and very few patients discontinued docetaxel due to side effects. Results of a quality of life analysis will be reported at a later time.

The difference in survival was not statistically significant between the SOC and SOC plus zoledronic acid arm. Addition of zoledronic acid to the combination of SOC and docetaxel yielded similar outcomes as SOC with only docetaxel.

Explore further: Treatment extends life for men with prostate cancer

More information: Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). abstracts.asco.org/156/AbstView_156_147721.html

Related Stories

Treatment extends life for men with prostate cancer

June 1, 2014
A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said Sunday.

Drug combination extends survival by more than a year in metastatic prostate cancer

June 2, 2014
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to ...

Study shows benefits for men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy

December 6, 2013
Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to ...

Liver metastases and its prognostic significance in men with metastatic prostate cancer

May 31, 2012
Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in ...

Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer

September 17, 2012
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...

Sipuleucel-T in prostate cancer: Indication of added benefit

March 20, 2015
Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.